Nobuyuki Tanaka

This inventor holds 17 USPTO granted patents and 1 published patent application, plus 5 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Shionogi Company Limited, Zeria Pharmaceutical Co., Ltd., Purdue Pharma L.p.. Active years: 1980-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nobuyuki Tanaka. Retrieved from https://idiyas.com/inventor/nobuyuki-tanaka-8e0duado

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 1)

% Patents Active = 70.6

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

Saitama, JP (2007)
Chuo-ku, JP (2013 - 2015)
Osaka, JP (1980 - 2018)
Toyonaka, JP (2017 - 2019)

Company Filing History:

6 out of 1,001

Shionogi Company Limited

patents

5 out of 45

Zeria Pharmaceutical Co., Ltd.

The University of New Mexico

patents

5. 2 out of 1,358

The University of Tokyo

University of California

Sumitomo Electric Industries, Limited

patents

10. 2 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1980-2019

Loading Chart...

Areas of Expertise:

Autotaxin Inhibitor

AMPK Activator

Pyrimidinone Derivative

Benzimidazole Compound

Aminothiazole Derivative

Tumorigenicity Diagnosis

Piperidine Compounds

Flexible Partition Membrane

Fused Pyrazole Derivative

Interferon Regulatory Factors

Oil/Water Storage Tank

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10189843 - Fused pyrazole derivative having autotaxin inhibitory activity (2019-01-29),

2. 10183949 - Pyrimidinone derivative having autotaxin-inhibitory activity (2019-01-22),

3. 10118927 - Substituted piperidin-4-amino-type compounds and uses thereof (2018-11-06),

4. 10093670 - Azabenzimidazole derivative having AMPK-activating activity (2018-10-09),

5. 9598411 - Substituted benzimidazole-type piperidine compounds and uses thereof (2017-03-21),

6. 9567330 - Azabenzimidazole derivative having AMPK-activating activity (2017-02-14),

7. 9133186 - Hetero ring-fused imidazole derivative having AMPK activating effect (2015-09-15),

8. 9000163 - Method for producing aminothiazole derivative and production intermediate (2015-04-07),

9. 8957219 - Acetic acid amide derivative having inhibitory activity on endothelial lipase (2015-02-17),

10. 8841461 - Method for producing aminothiazole derivative and production intermediate (2014-09-23),

11. 8772528 - Method for producing aminothiazole derivative and production intermediate (2014-07-08),

12. 8586761 - Method for producing aminothiazole derivative and production intermediate (2013-11-19),

13. 8011491 - Conveyance apparatus for an assembly line (2011-09-06),

14. 7276511 - Benzylamine derivative (2007-10-02),

15. 5807836 - Interferon regulatory factors 1 and 2 in the diagnosis of tumorigenicity (1998-09-15),

Title: Nobuyuki Tanaka: Innovator in Autotaxin Inhibition

Introduction

Nobuyuki Tanaka is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit autotaxin activity. With a total of 17 patents to his name, Tanaka's work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents is a fused pyrazole derivative that exhibits autotaxin inhibitory activity. This invention provides a compound of formula (1), characterized by specific substituents as defined in the description. The compound is intended for use in a pharmaceutical composition aimed at preventing or treating diseases associated with autotaxin. Another notable patent is a pyrimidinone derivative, which also demonstrates autotaxin-inhibitory activity. This compound is described in various forms, including its pharmaceutically acceptable salts.

Career Highlights

Throughout his career, Nobuyuki Tanaka has worked with reputable companies such as Shionogi & Company Limited and Zeria Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Tanaka has collaborated with notable colleagues, including Manabu Katou and Masaaki Nagasawa. These partnerships have likely contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Nobuyuki Tanaka's contributions to the field of pharmaceutical chemistry, particularly in autotaxin inhibition, highlight his innovative spirit and dedication to improving healthcare. His patents reflect a commitment to developing effective treatments for diseases linked to autotaxin activity.

Profile summary based on public USPTO records.